Microdosing Semaglutide: What the Evidence Actually Says About Sub-Therapeutic GLP-1 Use

“Microdosing semaglutide” and “how to microdose semaglutide” are among the most common GLP-1 patient searches, but the term is not defined anywhere in the clinical literature. It generally means using semaglutide at a dose below the FDA-approved maintenance (2.4 mg weekly for Wegovy) to get some of the appetite-suppression effect at a lower cost and with fewer side effects. This article answers what the published trial data actually shows about sub-therapeutic doses, what people mean by “how to” microdose (and why there is no validated protocol), how a microdose compares with a regular dose, and why the honest answer to “does it work?” is “less than a full dose, and less than most patients expect.” This is an educational explainer, not a dosing recommendation. The standard 0.25 mg titration start is the evidence-based low-dose approach; any dose decision belongs with your prescriber.

What the trial data shows about low-dose semaglutide

The STEP-1 trial^[1] is the closest the published literature comes to data on sub-therapeutic semaglutide dosing. STEP-1 used the standard titration ramp (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg) with 4 weeks at each step. The 0.25 mg starting dose is effectively a microdose — and the mean weight loss at the end of that 4-week step is roughly 1–1.5% of body weight. Not transformative, but not zero. Earlier, the phase-2 dose-ranging trial (O’Neil 2018^[2]) tested daily semaglutide from 0.05 mg up to 0.4 mg and found a clean, monotonic dose-response: the lowest doses produced the smallest weight loss, and effect climbed steadily with dose. That is the single best published evidence on what genuinely low doses do — and it points the same direction.

By the end of the 4-week 0.5 mg step (week 8), mean weight loss in STEP-1 was about 3%; by the end of the 1.0 mg step (week 12), about 6%; and after 68 weeks at the full 2.4 mg maintenance dose, the final endpoint was −14.9%^[1]. So the dose-response curve is steep and looks roughly like this:

Two caveats before reading these numbers as support for microdosing:

1. The early weight loss at lower doses is partly a novelty effect — anyone starting a reduced-calorie intervention loses weight in the first month, and that fades as the body adapts. The STEP-1 placebo arm lost about 0.5% in the first 4 weeks^[1], so the true drug-attributable loss at 0.25 mg is closer to 1% than 1.5%.
2. STEP-1 has no maintenance arm at 0.25, 0.5, 1.0, or 1.7 mg. No one stayed at those doses for six months or a year. Whether low-dose semaglutide produces meaningful sustained weight loss at a steady sub-therapeutic dose is not established by any published trial. The SUSTAIN diabetes program used lower maintenance doses (0.5 and 1.0 mg) and reported modest weight loss as a secondary endpoint, but in a diabetic population with a different metabolic profile — it is not a clean answer to the obesity microdosing question.

How to microdose semaglutide — the honest answer

People searching “how to microdose semaglutide” are usually looking for a dose, a schedule, and a number of syringe units. The honest answer is that no validated protocol exists. No randomized trial has held patients at a sub-therapeutic semaglutide dose to measure the outcome, so any specific dose-and-interval schedule circulating on social media or on some telehealth sites is improvised, not evidence-based. What the evidence does give you is the standard ladder: the label starts at 0.25 mg weekly for 4 weeks precisely because that low dose builds gut tolerance before stepping up^[5]. If your goal is the lowest effective, best-tolerated approach, the evidence-based tool is that titration ladder — not an internet microdose.

If a low-dose approach is on the table at all, it is an off-label clinical decision that belongs with a prescriber who documents the dose, plans lab and side-effect monitoring, and defines in advance how success will be judged. To see the label ladder mapped out, use our GLP-1 titration planner. If you are dosing a compounded vial and need to convert milligrams to insulin-syringe units, our unit converter and reverse dose calculator do the math, and the dose plotter shows how any dose builds up in the bloodstream. These tools compute what a number means — they do not tell you what dose to take, and neither does this article.

What is considered a microdose, and how many units?

There is no official or pharmacological definition. In practice, “microdose” is used loosely for any dose deliberately kept below the standard therapeutic range — most often either the 0.25 mg weekly starter dose held indefinitely, or a small self-chosen fraction of a compounded vial, with figures like 0.05–0.15 mg weekly circulating online. Translated to an insulin syringe, those are only a handful of units — but the exact unit count depends entirely on the vial's concentration, which varies between compounding pharmacies, so a “5-unit microdose” from one provider is a different amount of drug from another. Because no trial has defined a microdose, there is no validated number to target. Treat any specific microdose figure or unit count you see online as arbitrary rather than evidence-based, and let a prescriber set any dose.

Microdose vs regular dose: what you actually trade away

The dose-response table above is the clearest way to see the trade-off. A “regular” (FDA-approved maintenance) dose of 2.4 mg produced about 15% mean body-weight loss over 68 weeks^[1]; the sub-therapeutic steps produced single-digit percentages, and the true microdose region (0.25 mg and below) sits near the bottom of the curve. The Kushner overview of the STEP program^[3] frames the same point across all five pivotal trials: the large, durable outcomes were measured at the maintenance dose, not on the way up. So the trade with a microdose is real and predictable in direction — usually fewer side effects, and proportionally less of the proven benefit — even though the exact magnitude at a fractional dose is unstudied. You do not get STEP-level results from a microdose.

Why patients try microdosing

1. Cost. A lower dose means fewer units per week, so a compounded vial lasts longer and the monthly cost drops. This is the single biggest driver among compounded-telehealth patients.
2. Side-effect tolerance. Patients with severe nausea or GI intolerance on the full ramp sometimes hold a lower step as a tolerable compromise. Notably, the established fix for GI side effects is slower titration and standard GI-management strategies (Wharton 2022^[4]), not abandoning effective dosing.
3. Maintenance after weight loss. Patients at goal weight who want to prevent regain sometimes step the dose down rather than stopping. There is no FDA-approved reduced-dose maintenance protocol for this.
4. “Less drug = safer” intuition. A reasonable instinct, but the evidence base for sustained low-dose safety and efficacy is thin.

The off-label framework — what “off-label” actually means

Any dose below the FDA-approved maintenance is off-label for chronic weight management^[5][6]. Off-label use is legal — the FDA does not regulate how licensed prescribers write prescriptions, and off-label prescribing is a normal part of practice. But it also means:

• The dose has not been evaluated by the FDA for that specific indication and dose combination.
• Efficacy data for that specific dose is not in the approved label and is typically limited to investigator-initiated studies or patient experience.
• Insurance coverage for the off-label dose may be refused, especially for the commercial weight-management indication where prior authorizations are already strict.
• The prescriber takes full clinical responsibility for the decision; the patient takes full informed-consent responsibility.

The practical safety profile of low-dose use

STEP-1 documented the adverse-event profile at each dose step^[1]. Lower doses produce fewer GI side effects — nausea on 0.25 mg affected under 10% of patients, versus roughly 44% reporting nausea at some point across the full trial at higher doses. Chronic low-dose use is consistently better tolerated (Wharton 2022^[4]). The unknown is whether the rare but serious adverse events that appear at full dose (pancreatitis, gallbladder disease, the thyroid C-cell warning carried on the label^[5]) also appear at low dose — they probably do at a dose-proportional rate, but there is no dedicated long-term low-dose safety trial. Sourcing is the larger practical risk: microdosing overwhelmingly relies on compounded product, which is not FDA-approved and not subject to the same batch testing for identity and potency — see our microdosing Ozempic and GLP-1 overview for that side of it.

What an honest conversation with your prescriber looks like

1. What is the specific goal? Active weight loss, maintenance after loss, side-effect tolerance, or cost control? The answer shapes the right approach.
2. Active loss or maintenance? The STEP program showed continuing at the full 2.4 mg dose maintains weight loss while stopping produces rebound^[3]; whether a reduced maintenance dose sits somewhere in between is unstudied.
3. What dose, what interval, for how long? The specifics need to be in your medical record so monitoring can be designed around the actual regimen.
4. How will we know it's working? Define success criteria and decision points in advance. “We'll see how it goes” is a plan gap.
5. What's the exit plan? If the low dose underdelivers, do you go back to full dose, switch drugs, or something else?

Tools to run the dose math yourself

• GLP-1 titration planner — the evidence-based label ladder, step by step
• GLP-1 unit converter — mg ↔ insulin-syringe units for compounded vials
• Reverse dose calculator — work back from vial concentration to a target dose
• GLP-1 dose plotter — how any dose builds up in the bloodstream over time
• Split-dose calculator — for the split-injection question people group under “microdosing”

This article is educational and summarizes what the published trial data shows about low semaglutide doses. It is not a dose recommendation and does not constitute medical advice. Any decision about dosing — including any decision to use a GLP-1 at a dose below the FDA-approved maintenance — belongs between you and your prescriber. Weight Loss Rankings does not endorse off-label dosing and cannot replace the clinical judgment of a licensed healthcare provider.